Shearman & Sterling Advises Sun Pharmaceutical on Merger with Taro Pharmaceutical

Shearman & Sterling is advising Sun Pharmaceutical Industries Ltd. (Sun Pharma) on its merger agreement with Taro Pharmaceutical Industries Ltd. (Taro). Upon completion of the merger, Taro will become a privately held company, will be wholly owned by affiliates of Sun Pharma, and its ordinary shares will no longer be traded on the New York Stock Exchange. The closing of the merger is subject to certain terms and conditions customary for transactions of this type.

More >>

Tags:  Shearman & Sterling LLP | New York

Davis Polk – Sinopec Group Overseas Development (2012) Limited $500 Million Senior Notes

Davis Polk advised Goldman Sachs (Asia) L.L.C., Morgan Stanley & Co. International plc, CCB International Capital Limited and Mizuho Securities Asia Limited as initial purchasers in connection with the $500 million Regulation S offering by Sinopec Group Overseas Development (2012) Limited, a wholly owned subsidiary of China Petrochemical Corporation, of its 3.9% senior notes due 2022. The notes are to be consolidated and form a single class of notes with the $1 billion principal amount of 3.9% senior notes due 2022 issued on May 17, 2012.

More >>

Tags:  Davis Polk & Wardwell LLP | Hong Kong